Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
22 nov. 2022 05h00 HE
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
01 nov. 2022 09h05 HE
|
Jeito Capital
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
01 nov. 2022 06h02 HE
|
Jeito Capital
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
16 mars 2022 03h00 HE
|
Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
Jeito Capital co-leads $65 million Series A financing in EyeBio
22 févr. 2022 05h01 HE
|
Jeito Capital
Jeito Capital co-leads $65 million Series A financing in EyeBio EyeBio is a newly launched global company developing the next generation of eye disease therapiesFounded by two pioneers in...
Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics
29 nov. 2021 00h05 HE
|
Jeito Capital
Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for...
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)
20 sept. 2021 01h00 HE
|
Jeito Capital
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)Jeito I exceeds target and becomes the largest European fund...
Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round
15 juin 2021 01h00 HE
|
Jeito Capital
Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
27 mai 2021 02h00 HE
|
Jeito Capital
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders
14 déc. 2020 01h00 HE
|
Jeito Capital
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito’s third international investment in H2 2020, with deep and rapidly...